AMENDMENTS TO THE CLAIMS

1. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline ~~derivatives~~ derivative of the general formula (I)



(I)

wherein:

R^1 and R^2 independently represent hydrogen or C_1-C_4 alkoxy;

R^3 represents C_1-C_6-alkyl;

X represents -CH- or a nitrogen atom;

and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixture of diastereoisomeric racemates, or meso forms and pharmaceutically acceptable salts, solvent complexes and morphological forms, thereof.

2. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline ~~derivatives~~ derivative according to claim 1, wherein R^1 and R^2 both represent a C_1-C_4 alkoxy group.

3. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline ~~derivatives~~ derivative according to claim 2, wherein R^1 and R^2 both represent a methoxy group.

4. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline ~~derivatives~~ derivative according to ~~any of claims 1 to 3~~ claim 1, wherein X represents a nitrogen atom.

5. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline ~~derivatives~~ derivative according to ~~any of claims 1 to 3~~ claim 1, wherein X represents -CH-.

6. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline ~~derivatives~~ derivative according to ~~any of claims 1 to 5~~ claim 1, wherein R^3 represents a methyl group.

7. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline ~~derivatives~~ derivative according to ~~any of claims 1, 2, 3 or 5~~ claim 1, wherein R^1 and R^2 represent a methoxy group, X represents -CH- and R^3 represents C_1-C_6-alkyl.

8. (Currently amended) A 1,2,3,4-tetrahydroisoquinoline derivative according to ~~any of the claims 1 to 3~~ claim 1 selected from the group consisting of:

2-{6,7-Dimethoxy-1- [2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro-1*H*-iso-quinolin-2-yl}-*N*-methyl-2-phenyl-acetamide; and

2-{6,7-Dimethoxy-1-[2-(6-trifluoromethyl-pyridin-3-yl)-ethyl]-3,4-dihydro-1*H*-iso-quinolin-2-yl}-*N*-methyl-2-phenyl-acetamide.

9. (Cancelled).

10. (Currently amended) A pharmaceutical composition ~~containing~~ comprising at least one compound according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier material.

11-14. (Cancelled).

15. (New) A method of preventing or treating a disorder or disease associated with orexin system dysfunctions, comprising administering to a subject in need thereof an effective amount of the 1,2,3,4-tetrahydroisoquinoline derivative according to any one of claims 1 to 8.

16. (New) The method of claim 15, wherein said disorder or disease is selected from the group consisting of depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; schizophrenia; manic depression; delirium; dementia; severe mental retardation; Huntington's disease; Tourette syndrome; diabetes; appetite/taste disorders; vomiting/nausea; asthma; Parkinson's disease; Cushing's syndrome/disease; basophil adenoma; prolactinoma; hyperprolactinemia; hypopituitarism; hypophysis tumour/adenoma; hypothalamic diseases; inflammatory bowel disease; gastric dyskinesia; gastric ulcers; Froehlich's syndrome; hypophysis diseases, hypothalamic hypogonadism; Kallman's syndrome (anosmia, hyposmia); functional or psychogenic amenorrhea; hypothalamic hypothyroidism; hypothalamic-adrenal dysfunction; idiopathic hyperprolactinemia; hypothalamic disorders of growth hormone deficiency; idiopathic growth deficiency; dwarfism; gigantism; acromegaly; disturbed biological and circadian rhythms; sleep disturbances associated with neurological disorders, neuropathic pain, or restless leg syndrome; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ischemic or haemorrhagic stroke; subarachnoid haemorrhage; ulcers; allergies; benign prostatic hypertrophy; chronic renal failure; renal disease; impaired glucose tolerance; migraine; pain; hyperalgesia; causalgia; allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; pain related to HIV infection; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; irritable bowel

syndrome, migraine; angina; urinary bladder incontinence; tolerance to narcotics or withdrawal from narcotics; sleep disorders; eating disorders; cardiovascular disorders; neurodegenerative disorders; sleep apnea; narcolepsy; insomnia; parasomnia; and neurodegenerative disorders selected from the group consisting of disinhibition-dementia-parkinsonism-amyotrophy complex, pallido-ponto-nigral degeneration epilepsy, and seizure disorders.

17. (New) The method of claim 16, wherein said disorder or disease is an eating disorder or a sleep disorder.

18. (New) The method of claim 17, wherein said eating disorder is selected from the group consisting of metabolic dysfunction, dysregulated appetite control, compulsive obesities, emeto-bulimia and anorexia nervosa.

19. (New) The method of claim 17, wherein said sleep disorder is selected from the group consisting of insomnia, narcolepsy, excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, and delayed or advanced sleep phase syndrome.